ALK and non-small cell lung carcinoma: A mere four years after the discovery of the EML4-ALK fusion protein in 2007, crizotinib [19], a first-generation small-molecule inhibitor, was approved by the FDA as an ATP-competitive tyrosine kinase inhibitor for ALK-positive NSCLC patients [20].